Vamvakas, Spiros
European Medicines Agency
4 papers on CoChat
Most cited papers
- Verified
Clinician-Reported Outcome Assessments of Treatment Benefit: Report of the ISPOR Clinical Outcome Assessment Emerging Good Practices Task Force
Powers, J. H., Patrick, D. L., Walton, M. K., Marquis, P., Cano, S., Hobart, J., Isaac, M., Vamvakas, S., Slagle, A., Molsen, E., et al. (2017) · Value in Health
Health Systems, Economic Evaluations, Quality of LifeHealth Education and Validation
Cited by 191
- Verified
Identification and validation of biomarkers for autism spectrum disorders
Loth, E., Spooren, W., Ham, L. M., Isaac, M. B., Auriche-Benichou, C., Banaschewski, T., Baron-Cohen, S., Broich, K., Bölte, S., Bourgeron, T., et al. (2016) · Nature Reviews Drug Discovery
Autism Spectrum Disorder ResearchGenetics and Neurodevelopmental Disorders
Cited by 140
- Verified
Regulators' Advice Can Make a Difference: European Medicines Agency Approval of Zynteglo for Beta Thalassemia
Schuessler‐Lenz, M., Enzmann, H., & Vamvakas, S. (2020) · Clinical Pharmacology & Therapeutics
Biomedical Ethics and RegulationPharmaceutical Economics and Policy
Cited by 50
- Verified
The qualification of an enrichment biomarker for clinical trials targeting early stages of Parkinson’s disease
Stephenson, D., Hill, D., Cedarbaum, J. M., Tome, M., Vamvakas, S., Romero, K., Conrado, D. J., Dexter, D. T., Seibyl, J., Jennings, D., et al. (2019) · Journal of Parkinson’s Disease
Parkinson's Disease Mechanisms and TreatmentsDementia and Cognitive Impairment Research
Cited by 46
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free